A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model

References

• Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15(1):79–15. doi:https://doi.org/10.1128/CMR.15.1.79-94.2002.
   PubMed Web of Science ®Google Scholar
• de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215–26. doi:https://doi.org/10.2147/JIR.S165330.
   PubMed Web of Science ®Google Scholar
• Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24(Suppl 1):3–14. doi:https://doi.org/10.2165/11586290-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol. 2010;56:233–43.
   PubMedGoogle Scholar
• Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–13. doi:https://doi.org/10.3748/wjg.v22.i42.9300.
   PubMed Web of Science ®Google Scholar
• Corti A, Fassina G, Marcucci F, Barbanti E, Cassani G. Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem J. 1992;284(Pt 3):905–10. doi:https://doi.org/10.1042/bj2840905.
   PubMedGoogle Scholar
• Levin AD, Wildenberg ME, van den Brink GR. van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(8):989–97. doi:https://doi.org/10.1093/ecco-jcc/jjw053.
   PubMed Web of Science ®Google Scholar
• Marotte H, Cimaz R. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14(5):569–72. doi:https://doi.org/10.1517/14712598.2014.896334.
   PubMed Web of Science ®Google Scholar
• Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, Price VH, Grisham MB. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G135–46. doi:https://doi.org/10.1152/ajpgi.90462.2008.
   PubMed Web of Science ®Google Scholar
• Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39(6):711–23. doi:https://doi.org/10.1007/s10928-012-9280-2.
   PubMed Web of Science ®Google Scholar
• Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013;40(5):597–607. doi:https://doi.org/10.1007/s10928-013-9332-2.
   PubMed Web of Science ®Google Scholar
• Cao Y, Jusko WJ. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2014;41(4):375–87. doi:https://doi.org/10.1007/s10928-014-9372-2.
   PubMed Web of Science ®Google Scholar
• Chen X, Jiang X, Jusko WJ, Zhou H, Wang W. Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis. J Pharmacokinet Pharmacodyn. 2016;43(3):291–304. doi:https://doi.org/10.1007/s10928-016-9472-2.
   PubMed Web of Science ®Google Scholar
• Chen X, Jiang X, Doddareddy R, Geist B, McIntosh T, Jusko WJ, Zhou H, Wang W. Development and Translational application of a minimal physiologically based pharmacokinetic model for a monoclonal antibody against interleukin 23 (IL-23) in IL-23-induced psoriasis-like mice. J Pharmacol Exp Ther. 2018;365(1):140–55. doi:https://doi.org/10.1124/jpet.117.244855.
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67–86. doi:https://doi.org/10.1007/s10928-011-9232-2.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Oneda B, Yap LM, Jewell DP, Matters GL, Fitzpatrick LR, Seibold F, Sterchi EE, Ahmad T, Lottaz D, et al. MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease. Mucosal Immunol. 2009;2(3):220–31. doi:https://doi.org/10.1038/mi.2009.3.
   PubMed Web of Science ®Google Scholar
• Zheng T, Zhang B, Chen C, Ma J, Meng D, Huang J, Hu R, Liu X, Otsu K, Liu AC, et al. Protein kinase p38alpha signaling in dendritic cells regulates colon inflammation and tumorigenesis. Proc Natl Acad Sci U S A. 2018;115(52):E12313–E22. doi:https://doi.org/10.1073/pnas.1814705115.
   PubMed Web of Science ®Google Scholar
• Naeem M, Choi M, Cao J, Lee Y, Ikram M, Yoon S, Lee J, Moon HR, Kim MS, Jung Y, et al. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des Devel Ther. 2015;9:3789–99. doi:https://doi.org/10.2147/DDDT.S88672.
   PubMed Web of Science ®Google Scholar
• Cao Y, Jusko WJ. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2014;41(6):571–80. doi:https://doi.org/10.1007/s10928-014-9374-0.
   PubMed Web of Science ®Google Scholar
• Zhao J, Cao Y, Jusko WJ. Across-species scaling of monoclonal antibody pharmacokinetics using a minimal PBPK model. Pharm Res. 2015;32(10):3269–81. doi:https://doi.org/10.1007/s11095-015-1703-5.
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A, Wells JM. Intestinal permeability–a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189.
   PubMed Web of Science ®Google Scholar
• Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985;135:3972–77.
   PubMed Web of Science ®Google Scholar
• Chen X, DuBois DC, Almon RR, Jusko WJ. Interrelationships between infliximab and recombinant tumor necrosis factor-alpha in plasma using minimal physiologically based pharmacokinetic models. Drug Metab Dispos. 2017;45:790–97. doi:https://doi.org/10.1124/dmd.116.074807.
   PubMed Web of Science ®Google Scholar
• Spriggs DR, Deutsch S, Kufe DW. Genomic structure, induction, and production of TNF-alpha. Immunol Ser. 1992;56:3–34.
   PubMedGoogle Scholar
• Perrier C, de Hertogh G, Cremer J, Vermeire S, Rutgeerts P, Van Assche G, Szymkowski DE, Ceuppens JL. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis. 2013;19(2):246–53. doi:https://doi.org/10.1002/ibd.23023.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, Lu JF, Kamerud J, Ahene A, Myler H, et al. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. Aaps J. 2011;13(1):99–110. doi:https://doi.org/10.1208/s12248-011-9251-3.
   PubMed Web of Science ®Google Scholar
• Zheng S, McIntosh T, Wang W. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development–opportunities and challenges. J Clin Pharmacol. 2015;55(Suppl S3):S75–84. doi:https://doi.org/10.1002/jcph.357.
   PubMedGoogle Scholar
• Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3(1):61–66. doi:https://doi.org/10.4161/mabs.3.1.13799.
   PubMed Web of Science ®Google Scholar
• Wang W, Leu J, Watson R, Xu Z, Zhou H. Investigation of the mechanism of therapeutic protein-drug interaction between methotrexate and golimumab, an anti-tnfalpha monoclonal antibody. Aaps J. 2018;20(3):63. doi:https://doi.org/10.1208/s12248-018-0219-4.
   PubMed Web of Science ®Google Scholar
• Schwager S, Detmar M. Inflammation and Lymphatic Function. Front Immunol. 2019;10:308. doi:https://doi.org/10.3389/fimmu.2019.00308.
   PubMedGoogle Scholar
• Claesson-Welsh L. Vascular permeability–the essentials. Ups J Med Sci. 2015;120(3):135–43. doi:https://doi.org/10.3109/03009734.2015.1064501.
   PubMed Web of Science ®Google Scholar
• Pober JS, Sessa WC. Inflammation and the blood microvascular system. Cold Spring Harb Perspect Biol. 2014;7(1):a016345. doi:https://doi.org/10.1101/cshperspect.a016345.
   PubMed Web of Science ®Google Scholar
• Dragatin C, Polus F, Bodenlenz M, Calonder C, Aigner B, Tiffner KI, Mader JK, Ratzer M, Woessner R, Pieber TR, et al. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion. Exp Dermatol. 2016;25(2):157–59. doi:https://doi.org/10.1111/exd.12863.
   PubMed Web of Science ®Google Scholar
• Wang W, McIntosh TS, Jiang X, Doddareddy R, Dell EC, Zhou H. Deciphering the in vivo performance of a monoclonal antibody to neutralize its soluble target at the site of action in a mouse collagen-induced arthritis model. Pharm Res. 2016;33(4):1040–49. doi:https://doi.org/10.1007/s11095-015-1850-8.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang X, Doddareddy R, Fink D, McIntosh T, Davis HM, Zhou H. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys. Aaps J. 2014;16(1):129–39. doi:https://doi.org/10.1208/s12248-013-9545-8.
   PubMed Web of Science ®Google Scholar
• Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, Graham MA, Geboes K, Rousselle SD, Wagner CL, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313(2):578–85. doi:https://doi.org/10.1124/jpet.104.079277.
   PubMed Web of Science ®Google Scholar
• Van den Berghe N, Gils A, Thomas D. Achieving mucosal healing in inflammatory bowel diseases: which drug concentrations need to be targeted? Clin Pharmacol Ther. 2019;106(5):945–54. doi:https://doi.org/10.1002/cpt.1609.
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2016;10:915–27.
   PubMed Web of Science ®Google Scholar
• Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. Aaps J. 2009;11(2):371–80. doi:https://doi.org/10.1208/s12248-009-9112-5.
   PubMed Web of Science ®Google Scholar
• Alexander JS, Ganta VC, Jordan PA, Witte MH. Gastrointestinal lymphatics in health and disease. Pathophysiology. 2010;17(4):315–35. doi:https://doi.org/10.1016/j.pathophys.2009.09.003.
   PubMedGoogle Scholar
• Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35(5):573–91. doi:https://doi.org/10.1007/s10928-008-9102-8.
   PubMed Web of Science ®Google Scholar
• Nguyen DL, Limketkai B, Medici V, Saire Mendoza M, Palmer L, Bechtold M. Nutritional strategies in the management of adult patients with inflammatory bowel disease: dietary considerations from active disease to disease remission. Curr Gastroenterol Rep. 2016;18(10):55. doi:https://doi.org/10.1007/s11894-016-0527-8.
   PubMedGoogle Scholar